[go: up one dir, main page]

MX2018008050A - Agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada con estabilidad endopeptidasa neutral (nep) incrementada. - Google Patents

Agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada con estabilidad endopeptidasa neutral (nep) incrementada.

Info

Publication number
MX2018008050A
MX2018008050A MX2018008050A MX2018008050A MX2018008050A MX 2018008050 A MX2018008050 A MX 2018008050A MX 2018008050 A MX2018008050 A MX 2018008050A MX 2018008050 A MX2018008050 A MX 2018008050A MX 2018008050 A MX2018008050 A MX 2018008050A
Authority
MX
Mexico
Prior art keywords
controlled
release cnp
cnp agonists
increased nep
agonists
Prior art date
Application number
MX2018008050A
Other languages
English (en)
Inventor
Bernhard Ana
Sprogøe Kennett
Rau Harald
Hersel Ulrich
Cleemann Felix
Wegge Thomas
Original Assignee
Ascendis Pharma Growth Disorders As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendis Pharma Growth Disorders As filed Critical Ascendis Pharma Growth Disorders As
Publication of MX2018008050A publication Critical patent/MX2018008050A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Computer And Data Communications (AREA)

Abstract

La presente invención se refiere a agonistas de CNP de liberación controlada que tienen una semivida de degradación al menos 5 veces más en un ensayo de degradación NEP in vitro que el agonista del CNP liberado correspondiente, a composiciones farmacéuticas que comprenden tal agonista del CNP de liberación controlada, su uso y a métodos de tratamiento.
MX2018008050A 2016-01-08 2017-01-05 Agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada con estabilidad endopeptidasa neutral (nep) incrementada. MX2018008050A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP16150628 2016-01-08
EP16179289 2016-07-13
EP16191461 2016-09-29
PCT/EP2017/050213 WO2017118700A1 (en) 2016-01-08 2017-01-05 Controlled-release cnp agonists with increased nep stability

Publications (1)

Publication Number Publication Date
MX2018008050A true MX2018008050A (es) 2018-08-23

Family

ID=57851047

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018008050A MX2018008050A (es) 2016-01-08 2017-01-05 Agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada con estabilidad endopeptidasa neutral (nep) incrementada.

Country Status (15)

Country Link
US (3) US11224661B2 (es)
EP (1) EP3400018A1 (es)
JP (3) JP7076371B2 (es)
KR (1) KR20180100624A (es)
CN (2) CN114306629B (es)
AU (3) AU2017205690B2 (es)
BR (1) BR112018011152A2 (es)
CA (1) CA3008015A1 (es)
IL (2) IL259659B (es)
MX (1) MX2018008050A (es)
MY (1) MY195190A (es)
NZ (1) NZ743487A (es)
SG (1) SG11201805028RA (es)
WO (1) WO2017118700A1 (es)
ZA (1) ZA201804413B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY195190A (en) 2016-01-08 2023-01-11 Ascendis Pharma Growth Disorders As Controlled-Release Cnp Agonists With Increased Nep Stability
JP7051686B2 (ja) 2016-01-08 2022-04-11 アセンディス ファーマ グロース ディスオーダーズ エー／エス 大型のキャリアー部分を有するｃｎｐプロドラッグ
IL259658B2 (en) 2016-01-08 2024-06-01 Ascendis Pharma Growth Disorders As Controlled-release CNP agonists with reduced side effects
CA3007987C (en) 2016-01-08 2023-08-29 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with low npr-c binding
IL318754A (en) 2016-01-08 2025-04-01 Ascendis Pharma Growth Disorders As Controlled-release CNP agonists with low initial NPR-B activity
EP3400019B1 (en) 2016-01-08 2022-09-28 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with carrier attachment at the ring moiety
HUE062117T2 (hu) 2016-09-29 2023-09-28 Ascendis Pharma Growth Disorders As Kombinációs terápia szabályozott felszabadulású CNP agonistákkal
JP7571035B2 (ja) * 2019-02-11 2024-10-22 アセンディス ファーマ グロース ディスオーダーズ エー／エス Ｃｎｐコンジュゲートの乾燥医薬製剤
CN110006724B (zh) * 2019-04-17 2021-06-04 郑州安图生物工程股份有限公司 采用巴氏和革兰氏染色方法检测滴虫用试剂
WO2020254613A1 (en) * 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Controlled-release tyrosine kinase inhibitor compounds with localized pk properties
WO2020254612A1 (en) * 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Controlled-release tyrosine kinase inhibitor compounds with localized pd properties
US20230102309A1 (en) * 2019-06-21 2023-03-30 Ascendis Pharma Oncology Division A/S Tyrosine kinase inhibitor conjugates
WO2020254603A1 (en) * 2019-06-21 2020-12-24 Ascendis Pharma A/S CONJUGATES OF π-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS
EP4251150A4 (en) * 2020-11-25 2025-04-23 Prolynx LLC Extended-release hydrogel conjugates of C-natriuretic peptides
WO2023227505A1 (en) 2022-05-23 2023-11-30 Ascendis Pharma Growth Disorders A/S Liquid pharmaceutical formulations of cnp compounds
AR130935A1 (es) 2022-11-02 2025-02-05 Novo Nordisk As Compuestos de cnp
US20240315971A1 (en) * 2023-03-03 2024-09-26 Lotus Biopharma Inc. Microsphere formulations and methods of preparation thereof

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11510170A (ja) 1995-07-27 1999-09-07 ジェネンテック インコーポレーテッド タンパク質の処方
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
EP1118329A4 (en) 1998-09-28 2004-12-15 Santen Pharmaceutical Co Ltd LACRYMAL SECRETION PROMOTERS OR OPHTHALMOLOGICAL DROPS CONTAINING NATRIURETIC PEPTIDES AS ACTIVE INGREDIENTS FOR TREATING KERATOCONJUNCTIVITY
PE20010212A1 (es) 1999-06-01 2001-02-22 Neuralab Ltd Composiciones del peptido a-beta y procesos para producir las mismas
BRPI0203172B8 (pt) 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
MXPA04003333A (es) 2001-10-10 2006-02-22 Neose Technologies Inc Remodelado y glicoconjugacion de peptidos.
US7122189B2 (en) 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
PL377813A1 (pl) 2002-11-26 2006-02-20 Biocon Limited Modyfikowane związki natriuretyczne, ich koniugaty oraz zastosowania
US7332164B2 (en) 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
PL1620118T3 (pl) 2003-04-08 2014-11-28 Yeda Res & Dev Leki odwracalnie pegylowane
CA2763817C (en) 2003-04-08 2014-05-27 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
ES2741524T3 (es) 2004-03-23 2020-02-11 Ascendis Pharma Gmbh Profármaco polimérico con un enlazador autoinmolador
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
CU23556A1 (es) 2005-11-30 2010-07-20 Ct Ingenieria Genetica Biotech Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
JO3324B1 (ar) 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
US20100047258A1 (en) * 2006-08-02 2010-02-25 Dong Wang Drug Carriers, Their Synthesis, and Methods of Use Thereof
WO2008031045A2 (en) * 2006-09-08 2008-03-13 Mayo Foundation For Medical Education And Research Aquaretic and natriuretic polypeptides lacking vasodilatory activity
CN101534643A (zh) 2006-09-15 2009-09-16 安佐制药股份有限公司 用于递送寡核苷酸的基于位阻酯的生物可降解连接体
EP2091514B1 (en) 2006-11-09 2013-06-05 Alcon Research, Ltd. Water insoluble polymer matrix for drug delivery
AU2008231072B2 (en) 2007-03-22 2013-08-01 The Regents Of The University Of Colorado Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
KR20080098216A (ko) 2007-05-04 2008-11-07 한미약품 주식회사 캐리어 물질을 이용한 나트륨 배설 펩타이드 약물 결합체
ES2422007T3 (es) 2007-06-21 2013-09-06 Univ Muenchen Tech Proteínas activas biológicas que tienen estabilidad aumentada in vivo y/o in vitro
WO2009009712A1 (en) 2007-07-11 2009-01-15 Enzon Pharmaceuticals, Inc. Polymeric drug delivery system containing a multi-substituted aromatic moiety
CL2008003476A1 (es) * 2007-11-21 2009-08-14 Biomarin Pharm Inc Variante del peptido natriuretico de tipo c (cnp); composicion farmaceutica que la comprende; y su uso para tratar una displasia del esqueleto o un trastorno de la musculatura lisa vascular.
CN101903030A (zh) 2007-12-21 2010-12-01 灵感生物制药学有限公司 含海藻糖的稳定化因子ix制剂
HRP20191052T1 (hr) 2008-02-01 2019-11-01 Ascendis Pharma As Predlijek koji obuhvaća samocijepajuću poveznicu
JP2011520983A (ja) 2008-05-23 2011-07-21 エンゾン ファーマシューティカルズ，インコーポレーテッド オリゴヌクレオチドの送達のための細胞内遊離可能ジスルフィドリンカーを含有するポリマーシステム
WO2009156481A1 (en) 2008-06-25 2009-12-30 Ascendis Pharma As Pegylated bnp
WO2010033217A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of cd-np peptides
CN116925238A (zh) 2009-02-03 2023-10-24 阿穆尼克斯制药公司 延伸重组多肽和包含该延伸重组多肽的组合物
JP5718909B2 (ja) * 2009-05-20 2015-05-13 バイオマリン ファーマシューティカル インコーポレイテッド Ｃ型ナトリウム利尿ペプチドの変異体
WO2011012722A1 (en) 2009-07-31 2011-02-03 Ascendis Pharma As Prodrugs containing an aromatic amine connected by an amido bond to a linker
WO2011031441A1 (en) 2009-08-28 2011-03-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Therapy with a chimeric molecule and a pro-apoptotic agent
EP2512450B1 (en) 2009-12-15 2018-02-07 Ascendis Pharma Endocrinology Division A/S Dry growth hormone composition transiently linked to a polymer carrier
WO2011075471A2 (en) 2009-12-18 2011-06-23 Alcon Research, Ltd. Novel npr-b agonists and methods of use for the treatment of c-type natriuretic peptide-mediated disorders
CN102724967A (zh) 2009-12-31 2012-10-10 安龙制药公司 包括可释放的脲连接体的含芳香胺化合物的聚合缀合物
US9561285B2 (en) 2010-01-22 2017-02-07 Ascendis Pharma As Carrier-linked carbamate prodrug linkers
DK2525830T3 (en) 2010-01-22 2016-08-15 Ascendis Pharma As DIPEPTID-BASED PRODRUG LINKERS TO ALIFATIC AMINE-CONTAINING MEDICINES
EP2525829A1 (en) 2010-01-22 2012-11-28 Ascendis Pharma A/S Dipeptide-based prodrug linkers for aromatic amine-containing drugs
EP2552967A4 (en) 2010-04-02 2014-10-08 Amunix Operating Inc BINDING FUSION PROTEINS, BINDING FUSION PROTEIN MEDICINAL CONJUGATES, XTEN MEDICAMENT CONJUGATES, AND METHOD FOR THEIR PREPARATION AND USE
EP2566334B1 (en) 2010-05-05 2018-04-18 Prolynx, LLC Controlled drug release from solid supports
DK2566335T3 (en) 2010-05-05 2016-10-03 Prolynx Llc Controlled release of active ingredients from macromolecular CONJUGATES
SI2571510T1 (sl) 2010-05-21 2019-02-28 Xl-Protein Gmbh Biosintetični prolin/alaninski naključno zviti polipeptidi in njihove uporabe
EP2741782B1 (en) 2011-08-12 2020-05-06 Ascendis Pharma A/S Protein carrier-linked prodrugs
CN103857413A (zh) 2011-08-12 2014-06-11 阿森迪斯药物股份有限公司 载体连接的曲罗尼尔前药
CA2843503C (en) 2011-08-12 2020-12-22 Ulrich Hersel Polymeric hyperbranched carrier-linked prodrugs
US20140249093A1 (en) 2011-08-12 2014-09-04 Ascendis Pharma A/S Carrier-Linked Prodrugs Having Reversible Carboxylic Ester Linkages
CA2843875C (en) 2011-08-12 2020-01-07 Ascendis Pharma A/S High-loading water-soluble carrier-linked prodrugs
WO2013036857A1 (en) 2011-09-07 2013-03-14 Prolynx Llc Sulfone linkers
TWI578995B (zh) 2012-04-25 2017-04-21 第一三共股份有限公司 利尿鈉肽受體npr-b促效劑之用途
CA2868925C (en) 2012-04-25 2020-01-21 Ascendis Pharma A/S Prodrugs of hydroxyl-comprising drugs
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
JP6536871B2 (ja) 2013-12-02 2019-07-03 国立大学法人京都大学 Ｆｇｆｒ３病の予防および治療剤ならびにそのスクリーニング方法
US20170080049A1 (en) 2014-02-27 2017-03-23 Daiichi Sankyo Company, Limited Medicine against growth failure induced by administration of steroid
RU2693472C2 (ru) 2014-04-28 2019-07-03 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Лиофилизированный состав на основе hgf
AU2015299055C1 (en) 2014-08-06 2021-05-06 Ascendis Pharma A/S Prodrugs comprising an aminoalkyl glycine linker
RU2728656C2 (ru) 2015-01-09 2020-07-31 Асцендис Фарма Гроус Дизордерс А/С Cnp пролекарства
MX2018001314A (es) 2015-07-30 2018-05-28 Biomarin Pharm Inc Uso de variantes de peptido natriuretico de tipo c para tratar displasia esqueletica.
MX2018006986A (es) 2015-12-08 2018-09-05 Biomarin Pharm Inc Uso de variantes del peptido natriuretico tipo c para tratar osteoartritis.
EP3400019B1 (en) 2016-01-08 2022-09-28 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with carrier attachment at the ring moiety
MY195190A (en) 2016-01-08 2023-01-11 Ascendis Pharma Growth Disorders As Controlled-Release Cnp Agonists With Increased Nep Stability
CA3007987C (en) 2016-01-08 2023-08-29 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with low npr-c binding
JP7051686B2 (ja) 2016-01-08 2022-04-11 アセンディス ファーマ グロース ディスオーダーズ エー／エス 大型のキャリアー部分を有するｃｎｐプロドラッグ
IL318754A (en) 2016-01-08 2025-04-01 Ascendis Pharma Growth Disorders As Controlled-release CNP agonists with low initial NPR-B activity
IL259658B2 (en) 2016-01-08 2024-06-01 Ascendis Pharma Growth Disorders As Controlled-release CNP agonists with reduced side effects
HUE062117T2 (hu) 2016-09-29 2023-09-28 Ascendis Pharma Growth Disorders As Kombinációs terápia szabályozott felszabadulású CNP agonistákkal
AU2019320830A1 (en) 2018-08-16 2021-02-25 Beyondspring Pharmaceuticals, Inc. Method and composition for stimulating immune response
JP7571035B2 (ja) 2019-02-11 2024-10-22 アセンディス ファーマ グロース ディスオーダーズ エー／エス Ｃｎｐコンジュゲートの乾燥医薬製剤

Also Published As

Publication number Publication date
CN108472380A (zh) 2018-08-31
US12083182B2 (en) 2024-09-10
AU2024200659B2 (en) 2025-04-17
BR112018011152A2 (pt) 2018-11-21
JP2022110084A (ja) 2022-07-28
CN114306629B (zh) 2023-11-10
ZA201804413B (en) 2019-03-27
CA3008015A1 (en) 2017-07-13
WO2017118700A1 (en) 2017-07-13
IL293979A (en) 2022-08-01
AU2022209221B2 (en) 2023-12-14
US20220088206A1 (en) 2022-03-24
JP2019507725A (ja) 2019-03-22
JP7076371B2 (ja) 2022-05-27
IL259659B (en) 2022-08-01
AU2024200659A1 (en) 2024-02-22
JP2024113031A (ja) 2024-08-21
CN114306629A (zh) 2022-04-12
SG11201805028RA (en) 2018-07-30
US11224661B2 (en) 2022-01-18
HK1259384A1 (zh) 2019-11-29
IL293979B1 (en) 2024-04-01
AU2022209221A1 (en) 2022-09-29
IL259659A (en) 2018-07-31
US20250041431A1 (en) 2025-02-06
AU2017205690B2 (en) 2022-04-28
US20190022237A1 (en) 2019-01-24
NZ743487A (en) 2023-02-24
JP7499807B2 (ja) 2024-06-14
KR20180100624A (ko) 2018-09-11
AU2017205690A1 (en) 2018-06-07
EP3400018A1 (en) 2018-11-14
CN108472380B (zh) 2022-03-01
IL293979B2 (en) 2024-08-01
MY195190A (en) 2023-01-11

Similar Documents

Publication Publication Date Title
MX2018008050A (es) Agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada con estabilidad endopeptidasa neutral (nep) incrementada.
DOP2018000297A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
CL2023000198A1 (es) Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CL2018000299A1 (es) Composiciones con potenciadores de impregnacion para el suministro de fármacos.
CL2016002772A1 (es) Composiciones de insulina de rápida acción
CL2015001984A1 (es) (divisional de la sol. 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos.
CL2017001483A1 (es) Formulación de relación fija de insulina glargina/lixisenatida
CL2013001338A1 (es) Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
AR112015A1 (es) Composiciones sólidas para administración oral
CL2017002214A1 (es) Formulación de combinación de tesofensina y betabloqueante
CL2017001904A1 (es) Composición para el tratamiento de enfermedad veno-oclusiva hepática.
NI201500118A (es) Imidazopiridazinas sustituidas
CO2018005753A2 (es) Composición hemostática
BR112018011008A2 (pt) agonistas de cnp de liberação controlada com ligação a npr-c baixa
CL2018003045A1 (es) Semaglutida en afecciones cardiovasculares.
MX2022006903A (es) Productos orales con irritacion reducida.
AR102778A1 (es) Composición farmacéutica, su preparación y sus usos
MX380547B (es) Composición que comprende un inhibidor de fgfr1/kdr micronizado y el uso del mismo en el tratamiento de tumores neuroendocrinos.
NZ713440A (en) Nsaid administration and related compositions, methods and systems.
CO2017004809A2 (es) Composiciones de triptamidas
AR114030A1 (es) Triterpenos pentacíclicos en el tratamiento de una patología oral-dental
AR107282A1 (es) Agonista triple que tiene actividad para un receptor de glucagón, un receptor del péptido 1 similar al glucagón (glp-1) y un receptor de péptido insulinotrópico dependiente de glucosa (gip)
AR106477A1 (es) Combinación farmacéutica de antagonista del receptor nk3 y biguanidas
CL2016000542A1 (es) Composición que comprende hidroxipropil quitosano junto con excipientes y/o adyuvantes farmacéuticamente aceptables; útil en el tratamiento de la onicomicosis.